# Tyra Biosciences Advances Bladder Cancer Study as Midphase Results Disappoint Investors

Tyra Biosciences has released initial phase 2 data for its drug dabogratinib in bladder cancer, setting the company on track to launch a registrational study next year. The biotech’s stock fell in premarket trading after the complete response rate missed the level analysts had targeted.

The company reported the phase 2 results, which provide the basis for advancing toward a pivotal trial. Tyra intends to begin the registrational study in 2026. Dabogratinib is an investigational therapy being developed for patients with bladder cancer.

**Context**

Bladder cancer is one of the most common cancers worldwide, and treatment options remain limited for patients who do not respond to standard therapies. New targeted approaches, such as dabogratinib, could address an unmet medical need. The life sciences sector closely watches midphase readouts because they often determine whether a drug proceeds to the expensive, large-scale registrational trials that lead to regulatory approval.

Source: [Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock](https://www.fiercebiotech.com/biotech/tyra-rolls-toward-pivotal-bladder-cancer-study-even-midphase-data-deflates-stock)